Allspring Global Investments
CYT

Allspring Global Investments’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Allspring Global Investments’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,868
Closed -$10K – 3003
2022
Q1 		$10K Sell
2,868
-573
-17% -$3.26K ﹤0.01% 2970
2021
Q4 		$39K Buy
+3,441
New +$52.4K ﹤0.01% 2868

Other funds holding CYT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Allspring Global Investments's CYT Position: Q2 2022 in Review

Allspring Global Investments sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q2 2022, closing a stake of 2,868 shares — an estimated $10K sold.

Allspring Global Investments first reported a position in CYT in Q4 2021 and held it in 2 quarters. The position peaked at $39K in Q4 2021. 45 funds tracked by Wall St. Rank hold CYT as of Q2 2022.

  • Allspring Global Investments reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Allspring Global Investments sold 2,868 Cyteir Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $10K.
  • Allspring Global Investments first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
  • Allspring Global Investments's Cyteir Therapeutics, Inc. Common Stock position peaked at $39K in Q4 2021.
  • 45 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Allspring Global Investments's 13F filing for Q2 2022, filed 25 Jul 2022.